OOIR: Observatory of International Research

Papers

(The TQCC of Xenobiotica is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Expression of cytochrome P450 isozyme transcripts and activities in human livers	31
Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens	25
Amalgamation of in-silico, in-vitro and in-vivo approach to establish glabridin as a potential CYP2E1 inhibitor	16
Comparison between lab variability andin silicoprediction errors for the unbound fraction of drugs in human plasma	15
In silico prediction of volume of distribution of drugs in man using conformal prediction performs on par with animal data-based models	15
Pharmacokinetics, tissue distribution and excretion of five rhubarb anthraquinones in rats after oral administration of effective fraction of anthraquinones from rheum officinale	15
Oral bioavailability and pharmacokinetics of esculetin following intravenous and oral administration in rats	13
FXR activation prevents liver injury induced byTripterygium wilfordiipreparations	13
Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer–Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active m	12
Methyl-hydroxylation and subsequent oxidation to produce carboxylic acid is the major metabolic pathway of tolbutamide in chimeric TK-NOG mice transplanted with human hepatocytes	12
Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human	11
Newly identified tree shrew cytochrome P450 2B6 (CYP2B6) and pig CYP2B6b are functional drug-metabolising enzymes	11
Metal-metal interaction and metal toxicity: a comparison between mammalian and D. melanogaster	11
Effects of paeoniflorin on the activities and mRNA expression of rat CYP1A2, CYP2C11 and CYP3A1 enzymes in vivo	9
In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole	9
Pharmacokinetic changes of clozapine and norclozapine in a rat model of non-alcoholic fatty liver disease induced by orotic acid	9
Rapid determination of the pharmacokinetics and metabolic fate of gefitinib in the mouse using a combination of UPLC/MS/MS, UPLC/QToF/MS, and ion mobility (IM)-enabled UPLC/QToF/MS	9
Evaluation of the drug–drug interaction potential for trazpiroben (TAK-906), a D₂/D₃ receptor antagonist for gastroparesis, towards cytochrome P450s and transporters	8
Non-specific binding of compounds in in vitro metabolism assays: a comparison of microsomal and hepatocyte binding in different species and an assessment of the accuracy of prediction models	8
Curcumin-loaded hydroxypropyl-β-cyclodextrin inclusion complex with enhanced dissolution and oral bioavailability for epilepsy treatment	8
Preclinical pharmacokinetics, CYP phenotyping, and tissue distribution study of novel anti-breast cancer candidate S-011-1559	8
A comprehensive profiling and identification of liquiritin metabolites in rats using ultra-high-performance liquid chromatography coupled with linear ion trap–orbitrap mass spectrometer	8
Employing in vitro metabolism to guide design of F-labelled PET probes of novel α-synuclein binding bifunctional compounds	8
In vitro study of the drug–drug interaction potential of cetagliptin and clinical study of pharmacokinetic interaction of cetagliptin and metformin in healthy volunteers	8
The permeability characteristics and interaction of main components from Si-Ni-San in a MDCK epithelial cell monolayer model	7

Association of polymorphism of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR with the concentration of cyclosporin A in allogeneic haematopoietic stem cell transplantation recipients	7
Hepatotoxic effect of tramadol and O-desmethyltramadol in HepG2 cells and potential role of PI3K/AKT/mTOR	7
Preclinical in vitro and in vivo pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated ca	7
Roles of cytochrome P450 2A6 in the oxidation of flavone, 4′-hydroxyflavone, and 4′-, 3′-, and 2′-methoxyflavones by human liver microsomes	7
Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment	6
Metabolic activation of deferiprone mediated by CYP2A6	6
Absorption, distribution, metabolism, and excretion of three [¹⁴C]PBDE congeners in laying hens and transfer to eggs.	6
Metabolism, excretion, and pharmacokinetics of [¹⁴C]mirogabalin, a novel α₂δ ligand, in healthy volunteers following oral administration	6
In vitro metabolism, pharmacokinetics and drug interaction potentials of emvododstat, a DHODH inhibitor	6
In silico predictions of the human pharmacokinetics/toxicokinetics of 65 chemicals from various classes using conformal prediction methodology	6
Comprehensive identification, fragmentation pattern, and metabolic pathways of gefitinib metabolites via UHPLC-Q-TOF-MS/MS:in vivostudy of rat plasma, urine, bile, and faeces	6
Metabolic activation of zolmitriptan mediated by CYP2D6	6
A comprehensive analysis of six forms of cytochrome P450 2C (CYP2C) in pigs	6
Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans	6
Comparative HPLC-MS/MS-based pharmacokinetic studies of multiple diterpenoid alkaloids following the administration of Zhenwu Tang and Radix Aconiti Lateralis Praeparata extracts to rats	6
Molecular docking and oxidation kinetics of 3-phenyl coumarin derivatives by human CYP2A13	6
Metabolic exhaustion and casein kinase 1α drive deguelin-induced premature red blood cell death	6
Absorption, metabolism and excretion of pictilisib, a potent pan-class I phosphatidylinositol-3-Kinase (PI3K) inhibitor, in rats, dogs, and humans	6
Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects	5
Absorption, metabolism, and excretion of [¹⁴C]YY-20394, a highly selective PI3K-Delta inhibitor in humans	5
Meeting report: 3rd workshop of the peptide ADME discussion group	5
Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase	5
Evaluation of molecular markers GSTM1 and GSTT1 and clinical factors in breast cancer: case-control study and literature review	5
Population pharmacokinetics of methotrexate in paediatric patients with acute lymphoblastic leukaemia and malignant lymphoma	5
Influence of UGT2B7 and UGT1A6 polymorphisms on plasma concentration to dose ratio of valproic acid in Chinese epileptic children	5
Evaluation of species differences in the metabolism of the selective Na_V1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase	5
Polymorphisms in xenobiotic metabolism-related genes in patients with hepatocellular carcinoma: a case–control study	5
MicroRNA-mediated calcineurin signaling activation induces CCL2, CCL3, CCL5, IL8, and chemotactic activities in 4,4′-methylene diphenyl diisocyanate exposed macrophages	5
Comprehensive characterization and optimization of Caco-2 cells enabled the development of a miniaturized 96-well permeability assay	5
In silico ADME/tox comes of age: twenty years later	5
Metabolic map of the antiviral drug podophyllotoxin provides insights into hepatotoxicity	5
Comparison of mouse and human cytochrome P450 mediated-drug metabolising activities in hepatic and extrahepatic microsomes	5
Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of nafithromycin, a next generation lactone ketolide antibiotic	5
Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies	5
A discovery biotransformation strategy: combining in silico tools with high-resolution mass spectrometry and software-assisted data analysis for high-throughput metabolism	5
Effect of naringenin on the pharmacokinetics of metoprolol succinate in rats	5
Inhibitory effect of ketoconazole, quinidine and 1-aminobenzotriazole on pharmacokinetics of l-tetrahydropalmatine and its metabolite in rats	5
Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions	5
Differential in vitro interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters	4
ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)	4
Physiologically based pharmacokinetic modeling (PBPK) to predict drug-drug interactions for encorafenib. Part II. Prospective predictions in hepatic and renal impaired populations with clinical inhibi	4
Pirfenidone 5-hydroxylation is mainly catalysed by CYP1A2 and partly catalysed by CYP2C19 and CYP2D6 in the human liver	4
Characterisation of intravenous pharmacokinetics in Göttingen minipig and clearance prediction using established in vitro to in vivo extrapolation methodologies	4
Evaluation of urinary acetaminophen metabolites and its association with the genetic polymorphisms of the metabolising enzymes, and serum acetaminophen concentrations in preterm neonates with patent d	4
UDP-glucuronosyltransferase 1A4-mediated N2-glucuronidation is the major metabolic pathway of lamotrigine in chimeric NOG-TKm30 mice with humanised-livers	4
The common indoor air pollutant α-pinene is metabolised to a genotoxic metabolite α-pinene oxide	4
The metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [¹⁴C] cetagliptin in healthy volunteers	4
N-Acetyltransferase 2, glutathione S-transferase gene polymorphisms and susceptibility to hepatocellular carcinoma in an Algerian population	4
Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets from common m	4
In vitro modulatory effects of ginsenoside compound K, 20(S)-protopanaxadiol and 20(S)-protopanaxatriol on uridine 5′-diphospho-glucuronosyltransferase activity and expression	4

Metabolism of the antipsychotic drug olanzapine by CYP3A43	4
Quantitative prediction of OATP1B-mediated drug–drug interactions using endogenous biomarker coproporphyrin I	4
Drug–drug interaction comparison between tacrolimus and phenobarbital in different formulations for paediatrics and adults	4
Pomegranate peel polyphenols interaction with intestinal flora and its metabolic transformation	4
4-O-galloylalbiflorin inhibits the activity of CYP3A, 2C9, and 2D in human liver microsomes	4
Sex differences in the pharmacokinetics and tissue residues of Macleaya cordata extracts in rats	4
Pharmacokinetics of chelerythrine and its metabolite after oral and intramuscular administrations in pigs	4
Plasma and hepatic concentrations of acetaminophen and its primary conjugates after oral administrations determined in experimental animals and humans and extrapolated by pharmacokinetic modeling	4
The nuclear receptor REV-ERBα regulates CYP2E1 expression and acetaminophen hepatotoxicity	4
In vitro drug-drug interactions of decitabine and tetrahydrouridine involving drug transporters and drug metabolising enzymes	4
Metabolites identification and species comparison of Oroxylin A, an anti-cancer flavonoid, in vitro and in vivo by HPLC-Q-TOF-MS/MS	4
Tolerability, safety, pharmacokinetics and pharmacodynamics of SHR0534, a potent G protein-coupled receptor 40 (GPR40) agonist, at single- and multiple-ascending oral doses in healthy Chinese subjects	4
Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects	4
Population pharmacokinetics and dosage optimisation of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients	4
Identification of the metabolites produced following Iris tectorum Maxim oral administration and a network pharmacology-based analysis of their potential pharmacological properties	4
A cysteine trapping assay for risk assessment of reactive acyl CoA metabolites	4
Species differences in plasma protein binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir	4
Pharmacokinetics, tissue distribution, plasma protein binding rate and excretion of sinoacutine following intravenous administration in female and male Sprague-Dawley rats	4
Optimal pH 8.5 to 9 for the hydrolysis of vixotrigine and other basic substrates of carboxylesterase-1 in human liver microsomes	4
Physiologically based pharmacokinetic modelling to predict drug–drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and	4
Absorption, distribution, metabolism, and excretion of [¹⁴C]TPN729 after oral administration to rats	4